OSE-127

DRUG2 trials

Sponsors

OSE Immunotherapeutics

Conditions

Healthy SubjectsUlcerative Colitis

Phase 1

Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects

CompletedNCT03980080

OSE ImmunotherapeuticsHealthy Subjects

Start: 2018-12-19End: 2019-11-04Updated: 2019-12-12

Phase 2

Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis

CompletedNCT04882007

OSE ImmunotherapeuticsUlcerative Colitis

Start: 2020-10-02End: 2025-01-28Updated: 2026-06-23

Related Papers

OP36 Lusvertikimab, a first-in-class IL7 receptor antagonist, in moderate to severe Ulcerative Colitis: results of a multicenter, randomized, placebo-controlled phase II study

Journal of Crohn s and Colitis2025-01-013 citations

P0916 Lusvertikimab is efficacious in severe ulcerative colitis (UC) patients with high fecal calprotectin (FCP): results from the CoTikiS study

Journal of Crohn s and Colitis2025-01-011 citations

DOP031 Anti-IL-7 receptor plus anti-IL12/23 combination induces complete histological normalization in chronic colitis

Journal of Crohn s and Colitis2025-01-011 citations

CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Blood2024-11-05

Abstract 2957: CD127 is expressed by acute lymphoblastic leukemias and is efficiently targeted by the IL7R-antagonist OSE-127 through macrophage-mediated antibody dependent phagocytosis

Cancer Research2023-04-041 citations

P721 Treatment of Ulcerative Colitis with OSE-127 (lusvertikimab), a Strict IL-7Rα Antagonist, Non-Cytotoxic Monoclonal Antibody

Journal of Crohn s and Colitis2023-01-30

The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Blood2022-11-15